A clinical-stage bioelectronic medicine company developing electroceutical therapies for chronic autoimmune diseases.

SetPoint Medical is developing an implantable vagal nerve stimulator to reduce systemic inflammation in patients suffering from autoimmune diseases such as Rheumatoid arthritis (RA) and Crohn’s disease. The company’s novel insights into the connection between vagal nerve stimulation and the “inflammatory reflex” has the potential to significantly reduce systemic inflammation and the resulting structural damages. Vagal nerve stimulation provides a differentiated non-drug treatment option for patients with RA, requiring only a small incision and an increased safety profile compared to commonly used biologics. In early 2021, SetPoint began enrollment of its pivotal RESET-RA study, a multi-center, randomized, sham-controlled, double-blind clinical trial to evaluate the safety and efficacy of the SetPoint bioelectronic platform in patients with moderate-to-severe RA who are incomplete responders or are intolerant to biologic or targeted synthetic disease modifying anti-rheumatic drugs.

‍